Literature DB >> 12383772

A new generation of HIV vaccines.

Rama Rao Amara1, Harriet L Robinson.   

Abstract

WHO estimates that currently there are 40 million individuals living with HIV and there are 16000 new infections daily, worldwide. The best strategy to control the AIDS epidemic would be the development of an effective vaccine. New strategies for vaccine development have gained momentum over the past decade, some of which show greater promise in macaque models than did earlier protein-subunit or recombinant-canarypox strategies. These new vaccines include DNA vaccines and live viral vectors, and have been based on the generation of high levels of antiviral T cells. These vaccines do not prevent infection, but rather control virus replication with a rapid expansion and then contraction of antiviral T cells in response to the challenge infection. These recent vaccine successes in macaques raise hope that a vaccine can be developed that will successfully limit both the development of AIDS and viral transmission.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12383772     DOI: 10.1016/s1471-4914(02)02401-2

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  10 in total

1.  Structure and immunogenicity of alternative forms of the simian immunodeficiency virus gag protein expressed using Venezuelan equine encephalitis virus replicon particles.

Authors:  Chad Cecil; Ande West; Martha Collier; Christy Jurgens; Victoria Madden; Alan Whitmore; Robert Johnston; Dominic T Moore; Ronald Swanstrom; Nancy L Davis
Journal:  Virology       Date:  2007-02-01       Impact factor: 3.616

Review 2.  The good and evil of complement activation in HIV-1 infection.

Authors:  Qigui Yu; Richard Yu; Xuebin Qin
Journal:  Cell Mol Immunol       Date:  2010-03-15       Impact factor: 11.530

3.  Priming-boosting vaccination with recombinant Mycobacterium bovis bacillus Calmette-Guérin and a nonreplicating vaccinia virus recombinant leads to long-lasting and effective immunity.

Authors:  Yasushi Ami; Yasuyuki Izumi; Kazuhiro Matsuo; Kenji Someya; Masaru Kanekiyo; Shigeo Horibata; Naoto Yoshino; Koji Sakai; Katsuaki Shinohara; Sohkichi Matsumoto; Takeshi Yamada; Shudo Yamazaki; Naoki Yamamoto; Mitsuo Honda
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

Review 4.  Non-human primate models for AIDS vaccine research.

Authors:  Shiu-Lok Hu
Journal:  Curr Drug Targets Infect Disord       Date:  2005-06

5.  C3d enhances immune responses using low doses of DNA expressing the HIV-1 envelope from codon-optimized gene sequences.

Authors:  Joseph F Bower; Kelly L Sanders; Ted M Ross
Journal:  Curr HIV Res       Date:  2005-04       Impact factor: 1.581

6.  Functional human immunodeficiency virus type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and env expressed from a single rhabdovirus-based vaccine vector genome.

Authors:  James P McGettigan; Kristin Naper; Jan Orenstein; Martin Koser; Philip M McKenna; Matthias J Schnell
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

7.  Microarray profiling of antibody responses against simian-human immunodeficiency virus: postchallenge convergence of reactivities independent of host histocompatibility type and vaccine regimen.

Authors:  Henry E Neuman de Vegvar; Rama Rao Amara; Lawrence Steinman; Paul J Utz; Harriet L Robinson; William H Robinson
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

Review 8.  Animal Models for HIV Cure Research.

Authors:  Benjamin B Policicchio; Ivona Pandrea; Cristian Apetrei
Journal:  Front Immunol       Date:  2016-01-28       Impact factor: 7.561

9.  Mycobacterium bovis Bacille Calmette-Guérin as a Vaccine Vector for Global Infectious Disease Control.

Authors:  Kazuhiro Matsuo; Yasuhiro Yasutomi
Journal:  Tuberc Res Treat       Date:  2011-05-24

10.  A novel recombinant bacterial vaccine strain expressing dual viral antigens induces multiple immune responses to the Gag and gp120 proteins of HIV-1 in immunized mice.

Authors:  Yong Feng; Shiqun Wang; Fenglin Luo; Ying Ruan; Lei Kang; Xiaohui Xiang; Tao Chao; Guiqing Peng; Chengliang Zhu; Yongxin Mu; Ying Zhu; Xiaolian Zhang; Jianguo Wu
Journal:  Antiviral Res       Date:  2008-07-17       Impact factor: 5.970

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.